Log in

NASDAQ:INOInovio Pharmaceuticals Stock Price, Forecast & News

$14.75
+1.40 (+10.49 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.33
Now: $14.75
$14.92
50-Day Range
$7.14
MA: $11.59
$15.79
52-Week Range
$1.91
Now: $14.75
$19.36
Volume19.18 million shs
Average Volume28.95 million shs
Market Capitalization$2.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More
Inovio Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.11 million
Book Value$1.19 per share

Profitability

Net Income$-119,360,000.00
Net Margins-4,700.42%

Miscellaneous

Employees281
Market Cap$2.33 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

How has Inovio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INO stock has increased by 76.2% and is now trading at $14.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Inovio Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Inovio Pharmaceuticals.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Inovio Pharmaceuticals.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The biopharmaceutical company had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.55 million. Inovio Pharmaceuticals had a negative return on equity of 166.85% and a negative net margin of 4,700.42%. During the same period in the prior year, the business earned ($0.30) earnings per share. View Inovio Pharmaceuticals' earnings history.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

10 brokerages have issued 1-year target prices for Inovio Pharmaceuticals' stock. Their forecasts range from $4.00 to $19.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $12.33 in the next year. This suggests that the stock has a possible downside of 16.4%. View analysts' price targets for Inovio Pharmaceuticals.

Has Inovio Pharmaceuticals been receiving favorable news coverage?

Media coverage about INO stock has been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a news impact score of -4.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutInovio Pharmaceuticals.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Novavax (NVAX), Anavex Life Sciences (AVXL), Moderna (MRNA), Johnson & Johnson (JNJ), Opko Health (OPK) and Alibaba Group (BABA).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 56)
  • Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
  • Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
  • Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.91%), Wasatch Advisors Inc. (2.47%), VR Adviser LLC (1.83%), Nikko Asset Management Americas Inc. (1.86%), Sumitomo Mitsui Trust Holdings Inc. (1.86%) and Nikko Asset Management Americas Inc. (1.86%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau and Peter Kies. View institutional ownership trends for Inovio Pharmaceuticals.

Which institutional investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Morgan Stanley, Defender Capital LLC., UBS Group AG, and TIAA FSB. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, and Jong Joseph Kim. View insider buying and selling activity for Inovio Pharmaceuticals.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including VR Adviser LLC, BlackRock Inc., Balyasny Asset Management LLC, Geode Capital Management LLC, Nuveen Asset Management LLC, State Street Corp, IFG Advisory LLC, and Invesco Ltd.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau. View insider buying and selling activity for Inovio Pharmaceuticals.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $14.75.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $2.33 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.